Cargando…

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

Epidermal growth factor receptor (EGFR or HER-1) and its analog c-erbB-2 (HER-2) are protein tyrosine kinases correlated with prognosis and response to therapy in a variety of human cancers. KRAS mediates the transduction of signals between EGFR and the nucleus, and its mutation has been identified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terragni, Rossella, Casadei Gardini, Andrea, Sabattini, Silvia, Bettini, Giuliano, Amadori, Dino, Talamonti, Chiara, Vignoli, Massimo, Capelli, Laura, Saunders, Jimmy H., Ricci, Marianna, Ulivi, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893207/ https://www.ncbi.nlm.nih.gov/pubmed/24454858 http://dx.doi.org/10.1371/journal.pone.0085388

Ejemplares similares

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Correction: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?
Publicado: (2015)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)

p16 Immunostaining of Canine Squamous Cell Carcinomas Is Not Associated with Papillomaviral DNA
por: Sabattini, Silvia, et al.
Publicado: (2016)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Is Serum Total LDH Evaluation Able to Differentiate between Alimentary Lymphoma and Inflammatory Bowel Disease in a Real World Clinical Setting?
por: Terragni, Rossella, et al.
Publicado: (2016)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Ki‐67 assessment—agreeability between immunohistochemistry and flow cytometry in canine lymphoma
por: Rigillo, Antonella, et al.
Publicado: (2021)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

The Role of Fine Needle Aspiration of Liver and Spleen in the Staging of Low-Grade Canine Cutaneous Mast Cell Tumor
por: Rinaldi, Valentina, et al.
Publicado: (2022)

Lymphatic Drainage Mapping with Indirect Lymphography for Canine Mammary Tumors
por: Collivignarelli, Francesco, et al.
Publicado: (2021)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
por: Ulivi, Paola, et al.
Publicado: (2014)

Comparative Assessment of the Accuracy of Cytological and Histologic Biopsies in the Diagnosis of Canine Bone Lesions
por: Sabattini, S., et al.
Publicado: (2017)

Triple-Phase Multidetector Computed Tomography in Distinguishing Canine Hepatic Lesions
por: Stehlík, Ladislav, et al.
Publicado: (2020)

Comparison between Image-Guided Transbronchial Cryobiopsies and Thoracoscopic Lung Biopsies in Canine Cadaver: A Pilot Study
por: Falerno, Ilaria, et al.
Publicado: (2022)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Clinicopathologic features and biologic behavior of canine splenic nodules with stromal, histiocytic and lymphoid components
por: Sabattini, Silvia, et al.
Publicado: (2022)

Sentinel Lymph Node Mapping with Indirect Lymphangiography for Canine Mast Cell Tumour
por: De Bonis, Andrea, et al.
Publicado: (2022)

Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
por: Doyle, Hester A., et al.
Publicado: (2021)

Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020)

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease
por: Casadei Gardini, Andrea, et al.
Publicado: (2013)

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
por: Capelli, Laura, et al.
Publicado: (2016)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines
por: Zoli, Wainer, et al.
Publicado: (2005)

Peripheral Blood miR-328 Expression as a Potential Biomarker for the Early Diagnosis of NSCLC
por: Ulivi, Paola, et al.
Publicado: (2013)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Activating Mutations in PTPN11 and KRAS in Canine Histiocytic Sarcomas
por: Takada, Marilia, et al.
Publicado: (2019)

Potential Role of Hepatozoon canis in a Fatal Systemic Disease in a Puppy
por: De Bonis, Andrea, et al.
Publicado: (2021)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2dpgopf7lnjlvtsdk5gpkm4sov